CONTRACEPTION OPTIONS
Category
Behavioral
Methods
Continued
Medication
Failure
Contraception
Use at 1 Yr
Names
Rate* (%)
(%)
Abstinence / No
Method
Timing
Withdraw
Barrier
Methods
Best
Use
Common
Use
0
0-85
3-5
24
47
4
22
46
2
18
43
5
21
41
6
12
57
Cancer Specific Issues /
Contraindications
ADRs

Male Condom

Female Condom
Latex or
spermicide
sensitivities
can be seen


Diaphragm
Estrogen
Based
Methods
COCs
Transdermal
Patch
Lutera, Levora,
Yaz, Sprintec,
Ortho-Cyclin

0.3
9
67


Xulane
Ortho Evra
0.3
9
67



Increased risk
of VTE
Nausea/
Vomiting
Serum EE
levels higher
than 35 EE
COC
VTE risk
similar to 35
EE COC
Transient skin
reactions
More initial



These methods are
especially ineffective for
patients undergoing cancer
treatments. Discussions
should focus on counseling
more effective methods.
Condoms should be advised
in ALL sexually active AYA
patients to decrease the risk
of STI transmission
Diaphragm may be a good
option in hormone sensitive
cancer patients who cannot
have copper IUD
Advantageous  Should
for bone
be
health
avoided
in
cancer
Advantageous
pts if
for bone
possible
health
due to
Not
increase
recommended
d risk of
for patients
VTE
>90 kg
Link to
Handout
Fertility
Awareness
Withdraw
Male Condom
Female
Condom
Diaphragm
Birth Control
Pills
Patch
BTB than
COCs
Transvaginal Ring

Nuva Ring
0.3
Short or
Intermediate
acting
Progesterone
Methods
Progesterone only
Pills
LARC – nonhormonal
Implanon
Nexplanon
LNG IUD
Mirena
Skyla
Copper IUD
9
67
ParaGard





DMPA (DepoProvera)
Progesterone
implant,



0.2
LARC –
Progesterone
based
67
Norethindrone
(Ortho –
Micronor)
0.3
Injectable
progesterone
9
6
56




0.05
0.05
84

0.2
0.2
80
0.8
0.6
78
Serum EE
levels lower
than most
COCs
Headache
Vaginal
wetness
Breakthrough
bleeding
Headache
Nausea
Breast
tenderness
Acne
Irregular
vaginal
bleeding
Amenorrhea
Weight Gain
Transient
decrease in
bone mineral
density
May cause
unpredictable
vaginal
bleeding
Chance for
amenorrhea

May increase
menstrual
Ring
Progesterone
Pills

Not recommended in
treatments resulting in
osteopenia / osteoporosis
Depo-Provera

Irregular bleeding pattern
may not be best choice in
patients with concerns for
anemia
Used for treatment of
endometrial hyperplasia &
low grade cancer
May be considered for select
breast cancer patients on
Tamoxifen)
Implants



May not have
positive affect
on bone
health

First line for breast cancer
patients
IUDs
blood flow
Emergency
Combined OCPs
contraception LNG Methods
Ulipristal
Copper IUD
Yuzpe Method
Plan B/Next
Choice
Ella
ParaGard

NA
* = Percentage of women experiencing unintended pregnancy within the first year
N/V, Irregular
vaginal
bleeding.
Some breast
tenderness,
abdominal
pain, dizziness
, HA, fatigue.

Not recommended if
expecting concerning
anemia
Emergency
Contraception
There are absolutely no
situations in which risks
outweigh the benefits of EC